Advanced search

763 Results

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Sensei Biotherapeutics : Bio SNS-101 Data Webcast	09:11pm	PU
ASCO 2024: Topline SNS-101 Dose Escalation Data	06-01	PU
Idorsia announces changes to Idorsia Executive Committee and Board of Directors	05-21	GL
Atara Biotherapeutics Submits Tabelecleucel (Tab-cel®) Biologics License Application for Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease with U.S. FDA	05-20	BU
Atara Biotherapeutics Submits Tabelecleucel (Tab-cel) Biologics License Application for Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease with U.S. FDA	05-20	CI
Ono Pharmaceutical : Receives Approvals of BRAFTOVI® and MEKTOVI® for Expanded Use for Two New Indications in Japan	05-17	PU
Laboratory of America : Labcorp Announces Retirement of Dr. R. Sanders Williams and Mr. Jean-Luc Bélingard from Its Board of Directors	05-16	PU
Atara Biotherapeutics Announces First Quarter 2024 Financial Results and Operational Progress	05-09	BU
Togo votes amid tensions over constitutional reform	04-29	RE
Laboratory of America : Corporate Responsibility Report (Labcorp_Corporate_Responsibility_Report_2023_Final_v3_1)	04-08	PU
Laboratory of America : Corporate Responsibility Report (Labcorp_Corporate_Responsibility_Report_2023_Final_v3_2)	04-08	PU
Laboratory of America : 2023 Corporate Responsibility Report	04-08	PU
XOMA Corporation Announces Closing of Tender Offer	04-03	AQ
Atara Biotherapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Operational Progress	03-28	BU
ACELYRIN, INC. Announces Positive Phase 1/2 Proof-of-Concept Data for Lonigutamab, First Subcutaneous Anti-IGF-1R to Demonstrate Clinical Responses in Thyroid Eye Disease	03-20	GL
ACELYRIN, INC. Announces Positive Phase 1/2 Proof-of-Concept Data for Lonigutamab, First Subcutaneous Anti-IGF-1R to Demonstrate Clinical Responses in Thyroid Eye Disease	03-20	AQ
Kinnate Biopharma Inc. Sells Its Investigational Pan-RAF Inhibitor, Exarafenib, to Pierre Fabre Laboratories	03-04	AQ
Kinnate Biopharma Inc. Sells Its Investigational Pan-RAF Inhibitor, exarafenib, to Pierre Fabre Laboratories	03-01	PR
Kinnate Biopharma Inc. Sells Its Investigational Pan-RAF Inhibitor, Exarafenib, to Pierre Fabre Laboratories	03-01	AQ
Pfizer : Oncology Innovation Day Presentation	02-28	PU
Atara Biotherapeutics and Pierre Fabre Laboratories Announce Publication of Phase 3 ALLELE Tab-cel® Data in The Lancet Oncology	01-31	BU
Atara Biotherapeutics, Inc. and Pierre Fabre Laboratories Announce Publication of Phase 3 ALLELE Tab-cel®? Data in The Lancet Oncology	01-31	CI
Transcript : Elis SA, 2023 Sales/ Trading Statement Call, Jan 30, 2024	01-30
Transcript : Atara Biotherapeutics, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-11-2024 09:45 AM	01-11
Atara Biotherapeutics to Present Recent Progress and Key Upcoming Milestones at the 42nd Annual J.P. Morgan Healthcare Conference	01-08	BU
Acrivon Therapeutics Appoints Jean-Marie Cuillerot, M.D., as Chief Medical Officer	01-03	GL
Acrivon Therapeutics, Inc. Announces Management Changes	01-03	CI
Atara Biotherapeutics Announces Closing of Expanded Global Tab-cel® Partnership with Pierre Fabre Laboratories	12-20	BU
Atara Biotherapeutics, Inc. Announces Closing of Expanded Global Tab-Cel Partnership with Pierre Fabre Laboratories	12-20	CI
Atara Biotherapeutics Announces Primary Analysis Data from Phase 2 EMBOLD Clinical Trial of ATA188 in Non-Active Progressive Multiple Sclerosis	11-08	BU
Atara Biotherapeutics, Inc. Announces Primary Analysis Data from Phase 2 EMBOLD Clinical Trial of ATA188 in Non-Active Progressive Multiple Sclerosis	11-08	CI
ATARA BIOTHERAPEUTICS ANNOUNCES EXPANDED GLOBAL TAB-CEL PARTNERSHIP WITH PIERRE FABRE LABORATORIES AND THIRD QUARTER 2023 FINANCIAL RESULTS	11-02	AQ
Transcript : Atara Biotherapeutics, Inc., Q3 2023 Earnings Call, Nov 01, 2023	11-01
Atara Biotherapeutics : Investor Presentation	11-01	PU
Atara Biotherapeutics Announces Expanded Global Tab-cel® Partnership with Pierre Fabre Laboratories and Third Quarter 2023 Financial Results	11-01	BU
Atara Biotherapeutics, Inc. Announces Expanded Global Tab-Cel Partnership with Pierre Fabre Laboratories	11-01	CI
Immutep : ESMO 2023 - EFTISARC-NEO Trial in Progress Poster (Soft Tissue Sarcoma)	23-10-23	PU
DBV Technologies S.A. Announces Executive Changes	23-10-16	CI
DBV Technologies S.A. Appoints Virginie Boucinha as Principal Accounting Officer, Effective as of November 6, 2023	23-10-16	CI
DBV Technologies appoints new CFO	23-10-16	CF
DBV Technologies Announces Appointment of Virginie Boucinha as Chief Financial Officer	23-10-16	GL
U.S. FDA Approves Pfizer’s BRAFTOVI® + MEKTOVI® for BRAF V600E-Mutant Metastatic Non-Small Cell Lung Cancer	23-10-12	BU
U.S. FDA Approves Pfizer?s Braftovi® + Mektovi® for Braf V600e-Mutant Metastatic Non-Small Cell Lung Cancer	23-10-12	CI
Pierre Fabre Laboratories and Vernalis announce a drug discovery collaboration in oncology	23-09-26	AQ
ATARA BIOTHERAPEUTICS ANNOUNCES PLANS TO SUBMIT TAB-CEL BLA IN Q2 2024 FOLLOWING FDA AGREEMENT ON COMPARABILITY	23-09-20	AQ
Atara Biotherapeutics Announces Plans to Submit Tab-cel® BLA in Q2 2024 Following FDA Agreement on Comparability	23-09-19	BU
Transcript : Atara Biotherapeutics, Inc. Presents at Citi 18th Annual BioPharma Conference, Sep-07-2023 01:50 PM	23-09-07
Transcript : Gracell Biotechnologies Inc. Presents at Citi 18th Annual BioPharma Conference, Sep-07-2023 01:50 PM	23-09-07
Transcript : Cabaletta Bio, Inc. Presents at Citi 18th Annual BioPharma Conference, Sep-07-2023 01:50 PM	23-09-07
Atara Biotherapeutics : Investor Presentation	23-08-08	PU

No results for this search

Like the pros, access all the transcripts and spot the best opportunities before anyone else.

Unlock them now!

fermer